A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Nebivolol/valsartan (Primary) ; Nebivolol; Valsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 11 Jan 2017 Post hoc analysis results published in the Journal of Clinical Hypertension (Greenwich).
    • 06 Jun 2016 According to an Allergan media release, based on the results of this trial, the US FDA approved the BYVALSON (nebivolol and valsartan) 5 mg/ 80 mg tablets, fixed-dose combination (FDC) for the treatment of hypertension to lower blood pressure.
    • 19 May 2015 Post hoc subgroup analysis based on obesity status results presented at the 30th Annual Scientific Meeting of the American Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top